Abstract
BackgroundChimeric antigen receptor (CAR) T-cell therapy has been generally more effective in hematological malignancies than solid tumors. Considering the complex tumor microenvironment that plays a role in regulating lymphocyte responses...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
